Central Nervous System

Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug

Acumen Pharmaceuticals has announced the extension of its collaboration with Lonza to facilitate the anticipated commercial launch of sabirnetug, a new therapeutic for early Alzheimer's disease (AD).

Cipla enters deal to distribute Sanofi’s CNS products in India

Sanofi India Limited and Sanofi Healthcare India (together called “Sanofi India”) have entered into an exclusive partnership with Cipla, focusing on the expansion of its central nervous system (CNS) product portfolio in the Indian market.

Fermion receives IND approval in China for pain relief drug FZ008-145

Guangzhou Fermion Technology (Fermion) has received approval from China’s National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for FZ008-145.

CuraSen Therapeutics secures funding to advance CST-3056 for Alzheimer’s disease

CuraSen Therapeutics has secured up to $5.8m from the Alzheimer’s Drug Discovery Foundation (ADDF) to progress CST-3056 for the treatment of Alzheimer’s disease.

Biotech AltPep scores around $53m in Series B funding round

US-based amyloid diseases treatment solutions developer AltPep has raised $52.9m in its Series B investment round led by Senator Investment Group.

Ractigen receives orphan drug designation for ALS therapy

Ractigen Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its new therapeutic siRNA, RAG-17, to treat Amyotrophic Lateral Sclerosis (ALS).

Ryne Biotechnology receives CIRM grant to advance RNDP-001

Ryne Biotechnology has received a $4m Clinical Stage Research Program (CLIN1) grant from the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001.

Astex, MDI announce collaboration to identify neurodegenerative disease drugs

Astex and Cardiff University Medicines Discovery Institute (MDI) have announced a multi-year research collaboration which is aimed at identifying new drugs for the treatment of neurodegenerative diseases.

EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD

The European Medicines Agency (EMA) has accepted for review Eisai and Biogen’s marketing authorization application (MAA) submitted for lecanemab to treat early Alzheimer’s disease (AD).